Evaluation of the use of Hypertonic Saline 3% Nebulizer versus Intravenous Hypertonic Saline 3% to Attenuate the Manifestations of Acute Respiratory Distress Syndrome

Table 4: Duration of mechanical ventilation.

Groups	Days of Mechanical Ventilation									ANOVA
Groups	Range				Mean		±	SD		F		P-value
Group A	5		6		5.37			0.56		4.736		0.004*
Group B	4		5		4.26			0.43
Group C	5		6		5.25			0.62
Group D	3		4		3.12			4.81
Tukey's test
A & B		A & C		A & D		B & C			B & D		C & D
<0.001**		0.467		<0.001**		<0.001**			<0.001**		0.234

Group A (saline N): Standard pharmacotherapy +normal saline 0.9% (5ml) nebulizer /8hr.
Group B(H saline N): Standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
Group C((saline IV):Standard pharmacotherapy + normal saline 0.9% (500ml) intravenous /24hr.
Group D(H saline IV): Standard pharmacotherapy + hypertonic saline 3% (500ml) intravenous /24hr.
Arrows show groups with a statistically significant reduction in the duration of mechanical ventilation.